Baron Wealth Management LLC Takes Position in Hologic, Inc. (NASDAQ:HOLX)

Baron Wealth Management LLC bought a new position in Hologic, Inc. (NASDAQ:HOLX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,486 shares of the medical equipment provider’s stock, valued at approximately $203,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Prentiss Smith & Co. Inc. lifted its position in Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after purchasing an additional 130 shares during the period. Covestor Ltd boosted its holdings in Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after buying an additional 133 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its stake in shares of Hologic by 20.3% in the second quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock worth $62,000 after acquiring an additional 140 shares during the last quarter. Empirical Finance LLC grew its holdings in shares of Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after buying an additional 147 shares in the last quarter. Finally, Wedmont Private Capital raised its position in shares of Hologic by 3.7% in the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock valued at $361,000 after buying an additional 162 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Down 0.3 %

Shares of Hologic stock opened at $78.57 on Wednesday. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The company has a market cap of $18.25 billion, a P/E ratio of 23.59, a PEG ratio of 2.48 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The firm has a fifty day moving average of $80.56 and a two-hundred day moving average of $78.30.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.89 earnings per share. On average, analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on HOLX shares. Stephens reaffirmed an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Raymond James boosted their price objective on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Citigroup cut shares of Hologic from a “buy” rating to a “neutral” rating and lowered their price target for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. Finally, Mizuho cut their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.